Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus gemcitabine-based chemotherapy for first-line advanced biliary tract cancer
ChiCTR2000036652Phase 2Completed
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and gemcitabine in biliary cancer, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: overall survival. Started May 2020; status: completed.
02
Drugs
sintilimabgemcitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2000036652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036652.